Tectonic Therapeutic, Inc.
TX2100
Hereditary Hemorrhagic Telangiectasia (HHT)
Countdown
86days
Phase 1 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 1 trial results for TX2100 in Hereditary Hemorrhagic Telangiectasia (HHT) are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“The Company now expects to report topline results from the ongoing Phase 1a trial of TX2100 in healthy volunteers by the end of the third quarter of 2026.”